On October 25, 2022 Provectus (OTCQB: PVCT) reported that the Company has expanded its sponsored research program with James G. Krueger, MD, PhD, Co-director, Center for Clinical and Translational Science, D. Martin Carter Professor in Clinical Investigation, Senior Attending Physician, and head of the Laboratory of Investigative Dermatology at The Rockefeller University to investigate the potential for PH-10, a topical formulation of Provectus’ pharmaceutical-grade small molecule rose bengal sodium (RBS) drug substance, to directly alter the growth and differentiation of human keratinocytes, and to block cytokine-mediated signaling that creates different inflammatory skin diseases and may also be important in skin neoplasms (Press release, Provectus Biopharmaceuticals, OCT 25, 2022, View Source [SID1234622422]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PH-10 is an immuno-dermatology, multi-indication viable, clinical-stage pharmaceutical asset that the Company has used to treat more than 200 patients in multiple early- and mid-stage clinical trials for psoriasis and atopic dermatitis.

Dr. Krueger and the Laboratory of Investigative Dermatology plan to examine the effects of a wider range of PH-10 concentrations on human keratinocytes in vitro at the level of gene transcription. They also hope to determine PH-10’s interaction with and uptake by blood leukocytes, because these cells mediate inflammatory skin diseases and control or protect against some types of skin cancers.

The Kruger team previously elucidated several PH-10 mechanisms of action from work that it did as part of a Provectus clinical study of psoriasis, showing that:

PH-10 treatment significantly down-regulated IL-17A, IL-22, IL-26, IL-36, and keratin 16 genes,
Pathways significantly improved by PH-10 treatment included published psoriasis transcriptomes and cellular responses mediated by IL-17, IL-22, and interferons,
PH-10 treatment resulted in the downregulation of more than 500 disease-related genes, and
The expression of a wide-range of central "psoriasis-related" genes including IL-23, IL-17, IL-22, S100A7, IL-19, IL-36 and CXCL1 were effectively normalized to levels consistent with non-lesional skin.
A copy of the medical conference poster of this prior work by the Kruger team is available on Provectus’ website.